Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.
Corren J, Brightling CE, Boulet LP, Porsbjerg C, Wechsler ME, Menzies-Gow A, Ambrose CS, Cook B, Martin N, Spahn J, Llanos JP. Corren J, et al. Among authors: brightling ce. Eur Respir J. 2023 Mar 30;61(3):2202202. doi: 10.1183/13993003.02202-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36997233 Free article. No abstract available.
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Among authors: brightling ce. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update.
Levy ML, Bacharier LB, Bateman E, Boulet LP, Brightling C, Buhl R, Brusselle G, Cruz AA, Drazen JM, Duijts L, Fleming L, Inoue H, Ko FWS, Krishnan JA, Mortimer K, Pitrez PM, Sheikh A, Yorgancıoğlu A, Reddel HK. Levy ML, et al. NPJ Prim Care Respir Med. 2023 Feb 8;33(1):7. doi: 10.1038/s41533-023-00330-1. NPJ Prim Care Respir Med. 2023. PMID: 36754956 Free PMC article. Review.
Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design.
De Prado Gomez L, Pavord I, Busse W, Brightling CE, Wechsler ME, Rabe KF, Zhang M, Xing J, Jacob-Nara JA, Rowe PJ. De Prado Gomez L, et al. Among authors: brightling ce. ERJ Open Res. 2023 Mar 6;9(2):00417-2022. doi: 10.1183/23120541.00417-2022. eCollection 2023 Mar. ERJ Open Res. 2023. PMID: 36891077 Free PMC article.
Global access and patient safety in the transition to environmentally friendly respiratory inhalers: the Global Initiative for Asthma perspective.
Levy ML, Bateman ED, Allan K, Bacharier LB, Bonini M, Boulet LP, Bourdin A, Brightling C, Brusselle G, Buhl R, Chakaya MJ, Cruz AA, Drazen J, Ducharme FM, Duijts L, Fleming L, Inoue H, Ko FWS, Krishnan JA, Masekela R, Mortimer K, Pitrez P, Salvi S, Sheikh A, Reddel HK, Yorgancıoğlu A. Levy ML, et al. Lancet. 2023 Sep 16;402(10406):1012-1016. doi: 10.1016/S0140-6736(23)01358-2. Epub 2023 Jul 19. Lancet. 2023. PMID: 37480934 Review. No abstract available.
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.
Brightling CE, Caminati M, Llanos JP, Caveney S, Kotalik A, Griffiths JM, Lundahl A, Israel E, Pavord ID, Wechsler ME, Porsbjerg C, Corren J, Gołąbek M, Martin N, Ponnarambil S. Brightling CE, et al. Ann Allergy Asthma Immunol. 2024 Sep;133(3):310-317.e4. doi: 10.1016/j.anai.2024.04.031. Epub 2024 Apr 30. Ann Allergy Asthma Immunol. 2024. PMID: 38697286 Free article. Clinical Trial.
Development of a tool to detect small airways dysfunction in asthma clinical practice.
Kocks J, van der Molen T, Voorham J, Baldi S, van den Berge M, Brightling C, Fabbri LM, Kraft M, Nicolini G, Papi A, Rabe KF, Siddiqui S, Singh D, Vonk J, Leving M, Flokstra-de Blok B. Kocks J, et al. Eur Respir J. 2023 Mar 30;61(3):2200558. doi: 10.1183/13993003.00558-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36517179 Free PMC article.
Core outcome sets, developed collaboratively with patients, can improve the relevance and comparability of clinical trials.
Mathioudakis AG, Khaleva E, Fally M, Williamson PR, Jensen JU, Felton TW, Brightling C, Bush A, Winders T, Linnell J, Ramiconi V, Coleman C, Welte T, Roberts G, Vestbo J. Mathioudakis AG, et al. Eur Respir J. 2023 Apr 3;61(4):2202107. doi: 10.1183/13993003.02107-2022. Print 2023 Apr. Eur Respir J. 2023. PMID: 37012082 Free article. No abstract available.
416 results